3D cell panel screens for drug discovery and development

In this application note, Horizon Discovery describes the development of a parallel 3D OncoSignature service that enables screening across a panel of 200 cell lines in a spheroid format. This application note also demonstrates the use of patient-derived organoids as a powerful secondary screening tool to validate the findings of a 2D and spheroid-based 3D screens in a more complex 3D model system.